Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2011.07.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Conservative Reconstruction of the Lower Limb with a Bilayer Porous Collagen Matrix after a Spider Bite.
Adv Skin Wound Care
January 2025
Marco Palmesano, MD, is Plastic Reconstructive and Aesthetic Surgeon, PhD Program in Applied Medical Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. Davide Johan Bottini, MD, PhD, is Consultant in Maxillofacial Surgery, Policlinico Casilino Hospital, Rome. Also at University of Rome Tor Vergata, Gabriele Storti, MD, is Researcher and Consultant in Plastic Surgery; Lorenzo Secondi, MD, is Plastic Reconstructive and Aesthetic Surgeon, PhD Program in Applied Medical Surgical Sciences; and Carlo Cossi, MD; Alessio Calicchia, MD; Martina Giacalone, MD; and Irene Nunziata, MD, are Plastic Surgery Residents. Emanuela Basile, MD, is Consultant in Maxillofacial Surgery, Policlinico Casilino Hospital. Valerio Cervelli, MD, is Full Professor and Chief, Department of Plastic Surgery, University of Rome Tor Vergata.
Brown recluse spider bites may cause symptoms ranging from local cutaneous reactions to systemic visceral loxoscelism. Most bites are self-limiting, but some can lead to necrotic ulcerations with severe complications and soft tissue defects. Necrotizing ulcers are uncommon and have various clinical presentations, so no standard treatment exists.
View Article and Find Full Text PDFEULAR recommendations for the treatment of systemic sclerosis: 2023 update.
Ann Rheum Dis
January 2025
Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France.
Objectives: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies.
Methods: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review.
The Role of Serum HMGB-1 Level in Differentiating the Soft-Tissue Infection From Diabetic Foot Osteomyelitis.
J Am Podiatr Med Assoc
January 2025
†Medical Point Gaziantep Hospital, Gaziantep, Turkey.
Background: The incidence of diabetic foot infections is increasing due to the rising number of persons with diabetes and the prolonged life expectancy. It is vital to differentiate soft-tissue infection (STI) from diabetic foot osteomyelitis (DFO), as treatment modalities and durations vary widely, but this can be challenging. We aimed to assess the blood concentration levels of the high mobility group box 1 protein (HMGB-1) in STI and DFO compared to healthy subjects, and to investigate whether this protein could contribute to differentiating STI from DFO.
View Article and Find Full Text PDFGlycocalyx disruption, endothelial dysfunction and vascular remodeling as underlying mechanisms and treatment targets of chronic venous disease.
Int Angiol
December 2024
Vascular Surgery Research Laboratories, Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA -
The glycocalyx is an essential structural and functional component of endothelial cells. Extensive hemodynamic changes cause endothelial glycocalyx disruption and vascular dysfunction, leading to multiple arterial and venous disorders. Chronic venous disease (CVD) is a common disorder of the lower extremities with major health and socio-economic implications, but complex pathophysiology.
View Article and Find Full Text PDFComparing the Efficacy of a Unique Advanced Bioengineered Type-I Collagen-Based Skin Substitute Versus an Amnion Graft With Standard of Care in the Treatment of Non-healing Diabetic Foot Ulcers: A Randomized Clinical Trial.
Cureus
January 2025
Research and Development, Encoll Corporation, Fremont, USA.
The increased cost and morbidity associated with diabetic foot ulcers (DFUs) place a substantial strain on the entire global healthcare system. In this trial, 24 subjects with a chronic DFU, Wagner grade 1 (University of Texas grade 1A), were treated with Standard of Care (SOC) therapy and randomized, one-half to receive advanced high-purity Type-I collagen-based skin substitute (HPTC; manufactured by Encoll Corp., Fremont, CA, USA), and the other half to receive a dehydrated human amnion/chorion membrane (dHACM) or viable cryopreserved human placental membrane (vCHPM).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!